Skip to main navigation Skip to search Skip to main content

Ginsenoside-Rb1 as an anti-cancer therapeutic: abridged secondary publication

Research output: Contribution to journalJournal articlepeer-review

3 Citations (Scopus)

Abstract

Recurrence of cancer despite chemotherapy is associated with high mortality. Cancer stem cells (CSCs) have been reported to possess properties of self-renewal, differentiation, and drug resistance that lead to tumorigenesis and chemoresistance. They are not eliminated by conventional chemotherapy owing to their distinct molecular signatures. Thus, understanding CSCs’ biology and targeting them are important.

Saponins have been shown to exhibit potent cytotoxic effects as chemotherapeutics. Ginsenoside-Rb1 isolated from ginseng (0.37%-0.5%) is a notable saponin. After being taken orally, about 70% of Rb1 is metabolised to 20-O-β-Dglucopyranosyl-20(S)-protopanaxadiol (compound K) by gut microbes. This metabolite can be readily absorbed into the blood and retained in the body.
Original languageEnglish
Pages (from-to)16-17
Number of pages2
JournalHong Kong Medical Journal
Volume26
Issue number6
Publication statusPublished - Dec 2020

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Ginsenoside-Rb1 as an anti-cancer therapeutic: abridged secondary publication'. Together they form a unique fingerprint.

Cite this